Symbols / HALO Stock $65.36 -1.85% Halozyme Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
HALO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Exch · Country NMS · United States
Market Cap 7.74B
Enterprise Value 9.75B
Income 316.89M
Sales 1.40B
FCF (ttm) 184.83M
Book/sh 0.41
Cash/sh 1.21
Employees 423
Insider 10d —
IPO Mar 16, 2004
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 25.53
Forward P/E 6.63
PEG —
P/S 5.54
P/B 157.87
P/C —
EV/EBITDA 10.86
EV/Sales 6.98
Quick Ratio 3.30
Current Ratio 4.66
Debt/Eq 4,460.19
LT Debt/Eq —
EPS (ttm) 2.56
EPS next Y 9.86
EPS Growth —
Revenue Growth 51.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-05
Earnings (prior) 2026-02-17
ROA 22.24%
ROE 153.59%
ROIC —
Gross Margin 77.79%
Oper. Margin 56.31%
Profit Margin 22.69%
Shs Outstand 118.47M
Shs Float 116.71M
Insider Own 1.08%
Instit Own 107.99%
Short Float 15.57%
Short Ratio 9.92
Short Interest 14.26M
52W High 82.22
vs 52W High -20.51%
52W Low 47.50
vs 52W Low 37.60%
Beta 1.03
Impl. Vol. 54.20%
Rel Volume 0.78
Avg Volume 1.76M
Volume 1.38M
Target (mean) $85.22
Tgt Median $90.00
Tgt Low $57.00
Tgt High $96.00
# Analysts 9
Recom Buy
Prev Close $66.59
Price $65.36
Change -1.85%
About

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$85.22
Mean price target
2. Current target
$65.36
Latest analyst target
3. DCF / Fair value
$28.08
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$65.36
Low
$57.00
High
$96.00
Mean
$85.22

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-19 main Benchmark Buy → Buy $90
2026-02-19 main Wells Fargo Equal-Weight → Equal-Weight $75
2026-01-08 main TD Cowen Buy → Buy $90
2025-12-19 reit HC Wainwright & Co. Buy → Buy $90
2025-11-28 reit HC Wainwright & Co. Buy → Buy $90
2025-11-18 main Goldman Sachs Neutral → Neutral $56
2025-11-04 main Citizens Market Outperform → Market Outperform $92
2025-10-27 main JP Morgan Neutral → Neutral $65
2025-10-20 main Morgan Stanley Overweight → Overweight $79
2025-10-15 reit HC Wainwright & Co. Buy → Buy $90
2025-10-14 up Leerink Partners Underperform → Market Perform $70
2025-10-02 main HC Wainwright & Co. Buy → Buy $90
2025-09-24 main Benchmark Buy → Buy $90
2025-09-22 main HC Wainwright & Co. Buy → Buy $85
2025-08-18 main Morgan Stanley Overweight → Overweight $80
2025-08-07 main JP Morgan Neutral → Neutral $63
2025-08-06 main JMP Securities Market Outperform → Market Outperform $91
2025-08-06 main HC Wainwright & Co. Buy → Buy $75
2025-08-06 up Morgan Stanley Equal-Weight → Overweight $75
2025-07-16 main JP Morgan Neutral → Neutral $60
News
RSS: Latest HALO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-06 TORLEY HELEN I Chief Executive Officer — 10,000 $63.14 $634,982
2026-04-06 TORLEY HELEN I Chief Executive Officer — 10,000 $12.07 $120,700
2026-04-02 TORLEY HELEN I Chief Executive Officer — 40,000 $64.06 $2,592,237
2026-04-02 TORLEY HELEN I Chief Executive Officer — 40,000 $12.07 $482,800
2026-03-10 CAUDILL CORTNEY Chief Operating Officer — 28,857 $67.64 $1,955,160
2026-03-10 CAUDILL CORTNEY Chief Operating Officer — 21,546 $33.51 $722,006
2026-03-04 TORLEY HELEN I Chief Executive Officer — 50,000 $68.85 $3,476,157
2026-03-04 TORLEY HELEN I Chief Executive Officer — 50,000 $12.07 $603,500
2026-02-23 TORLEY HELEN I Chief Executive Officer — 39,193 — —
2026-02-23 SNYDER MARK HOWARD Officer — 12,343 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1,396.61
+37.55%
1,015.32
+22.44%
829.25
+25.62%
660.12
Operating Revenue
1,396.61
+37.55%
1,015.32
+22.44%
829.25
+25.62%
660.12
Cost Of Revenue
228.77
+43.51%
159.42
-17.13%
192.36
+38.09%
139.30
Reconciled Cost Of Revenue
217.38
+45.75%
149.15
-17.72%
181.28
+36.49%
132.81
Gross Profit
1,167.84
+36.44%
855.91
+34.39%
636.89
+22.29%
520.81
Operating Expense
365.24
+19.98%
304.43
+1.71%
299.32
+18.18%
253.28
Research And Development
81.49
+3.09%
79.05
+3.52%
76.36
+14.65%
66.61
Selling General And Administration
207.09
+34.18%
154.34
+3.45%
149.18
+3.94%
143.53
Total Expenses
594.02
+28.06%
463.85
-5.66%
491.68
+25.24%
392.58
Operating Income
802.59
+45.54%
551.48
+63.36%
337.57
+26.18%
267.53
Total Operating Income As Reported
469.01
-14.95%
551.48
+63.36%
337.57
+26.18%
267.53
EBITDA
573.05
-12.72%
656.54
+45.27%
451.95
+43.25%
315.51
Normalized EBITDA
890.64
+40.75%
632.79
+49.80%
422.43
+33.19%
317.17
Reconciled Depreciation
88.05
+8.29%
81.31
-4.18%
84.86
+70.94%
49.64
EBIT
485.00
-15.69%
575.23
+56.70%
367.09
+38.07%
265.87
Total Unusual Items
-317.59
-1437.12%
23.75
-19.53%
29.52
+1871.73%
-1.67
Total Unusual Items Excluding Goodwill
-317.59
-1437.12%
23.75
-19.53%
29.52
+1871.73%
-1.67
Special Income Charges
-339.06
0.00
-100.00%
13.20
+586.73%
-2.71
Other Special Charges
5.48
—
—
2.71
Impairment Of Capital Assets
48.70
0.00
0.00
—
Restructuring And Mergern Acquisition
284.89
0.00
+100.00%
-13.20
0.00
Net Income
316.89
-28.64%
444.09
+57.71%
281.59
+39.31%
202.13
Pretax Income
466.88
-16.20%
557.13
+59.94%
348.33
+39.94%
248.92
Net Non Operating Interest Income Expense
-18.13
-0.17%
-18.09
+3.56%
-18.76
-10.71%
-16.95
Interest Expense Non Operating
18.13
+0.17%
18.09
-3.56%
18.76
+10.71%
16.95
Net Interest Income
-18.13
-0.17%
-18.09
+3.56%
-18.76
-10.71%
-16.95
Interest Expense
18.13
+0.17%
18.09
-3.56%
18.76
+10.71%
16.95
Other Income Expense
-317.59
-1437.12%
23.75
-19.53%
29.52
+1871.73%
-1.67
Gain On Sale Of Security
21.47
-9.60%
23.75
+45.57%
16.32
+1459.94%
1.05
Tax Provision
149.99
+32.68%
113.04
+69.39%
66.73
+42.63%
46.79
Tax Rate For Calcs
0.00
+58.35%
0.00
+6.06%
0.00
+1.76%
0.00
Tax Effect Of Unusual Items
-102.04
-2217.38%
4.82
-14.65%
5.65
+1902.83%
-0.31
Net Income Including Noncontrolling Interests
316.89
-28.64%
444.09
+57.71%
281.59
+39.31%
202.13
Net Income From Continuing Operation Net Minority Interest
316.89
-28.64%
444.09
+57.71%
281.59
+39.31%
202.13
Net Income From Continuing And Discontinued Operation
316.89
-28.64%
444.09
+57.71%
281.59
+39.31%
202.13
Net Income Continuous Operations
316.89
-28.64%
444.09
+57.71%
281.59
+39.31%
202.13
Normalized Income
532.44
+25.23%
425.16
+64.97%
257.72
+26.66%
203.48
Net Income Common Stockholders
316.89
-28.64%
444.09
+57.71%
281.59
+39.31%
202.13
Diluted EPS
2.56
-25.36%
3.43
+63.33%
2.10
+45.83%
1.44
Basic EPS
2.64
-24.57%
3.50
+64.32%
2.13
+43.92%
1.48
Basic Average Shares
119.84
-5.51%
126.83
-3.87%
131.93
-3.59%
136.84
Diluted Average Shares
123.90
-4.27%
129.42
-3.56%
134.20
-4.56%
140.61
Diluted NI Availto Com Stockholders
316.89
-28.64%
444.09
+57.71%
281.59
+39.31%
202.13
Amortization
76.66
+7.90%
71.05
-3.69%
73.77
+70.98%
43.15
Amortization Of Intangibles Income Statement
76.66
+7.90%
71.05
-3.69%
73.77
+70.98%
43.15
Depreciation Amortization Depletion Income Statement
76.66
+7.90%
71.05
-3.69%
73.77
+70.98%
43.15
Depreciation And Amortization In Income Statement
76.66
+7.90%
71.05
-3.69%
73.77
+70.98%
43.15
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
2,525.32
+22.38%
2,063.48
+19.05%
1,733.27
-5.88%
1,841.51
Current Assets
825.21
-23.97%
1,085.34
+45.41%
746.42
+1.00%
739.01
Cash Cash Equivalents And Short Term Investments
142.82
-76.04%
596.07
+77.40%
336.00
-7.39%
362.79
Cash And Cash Equivalents
133.82
+15.51%
115.85
-2.13%
118.37
-49.46%
234.19
Other Short Term Investments
9.00
-98.13%
480.22
+120.66%
217.63
+69.23%
128.60
Receivables
441.27
+43.06%
308.45
+31.70%
234.21
+1.36%
231.07
Accounts Receivable
434.27
+46.25%
296.94
+23.72%
240.00
+27.06%
188.88
Gross Accounts Receivable
—
—
240.00
+27.06%
188.88
Allowance For Doubtful Accounts Receivable
—
—
-6.75
-252.51%
-1.91
Receivables Adjustments Allowances
-9.61
-9.95%
-8.74
-29.49%
-6.75
-252.51%
-1.91
Other Receivables
16.61
-17.97%
20.25
+2018.31%
0.96
-97.83%
44.10
Inventory
176.47
+24.40%
141.86
+11.17%
127.60
+27.44%
100.12
Raw Materials
—
—
23.65
+71.45%
13.79
Work In Process
—
—
34.02
-15.70%
40.36
Finished Goods
—
—
69.93
+52.12%
45.97
Prepaid Assets
—
—
—
—
Other Current Assets
64.64
+65.95%
38.95
-19.88%
48.61
+7.97%
45.02
Net PPE
82.14
+9.46%
75.03
+0.12%
74.94
-0.83%
75.57
Gross PPE
115.30
+14.76%
100.46
+6.19%
94.61
+4.74%
90.33
Accumulated Depreciation
-33.16
-30.40%
-25.43
-29.34%
-19.66
-33.24%
-14.76
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
9.91
+2.08%
9.71
-0.12%
9.72
+23.77%
7.86
Other Properties
97.86
+16.86%
83.74
+7.50%
77.90
+2.84%
75.74
Leases
7.52
+7.26%
7.01
+0.36%
6.99
+3.83%
6.73
Goodwill And Other Intangible Assets
1,561.83
+90.78%
818.65
-7.99%
889.70
-6.91%
955.70
Goodwill
580.36
+39.23%
416.82
+0.00%
416.82
+1.90%
409.05
Other Intangible Assets
981.47
+144.25%
401.83
-15.02%
472.88
-13.50%
546.65
Non Current Deferred Assets
0.00
-100.00%
3.85
-12.11%
4.39
-90.13%
44.43
Non Current Deferred Taxes Assets
0.00
-100.00%
3.85
-12.11%
4.39
-90.13%
44.43
Non Current Prepaid Assets
—
—
—
—
Other Non Current Assets
56.15
-30.33%
80.60
+352.38%
17.82
-33.52%
26.80
Total Liabilities Net Minority Interest
2,476.51
+45.71%
1,699.66
+3.04%
1,649.46
-1.33%
1,671.71
Current Liabilities
177.09
+27.31%
139.10
+23.65%
112.49
-13.99%
130.79
Payables And Accrued Expenses
177.09
+27.31%
139.10
+23.65%
112.49
-4.22%
117.45
Payables
20.90
+103.91%
10.25
-13.26%
11.82
-33.22%
17.69
Accounts Payable
20.90
+103.91%
10.25
-13.26%
11.82
-33.22%
17.69
Current Accrued Expenses
156.19
+21.22%
128.85
+27.98%
100.68
+0.92%
99.76
Current Debt And Capital Lease Obligation
—
—
—
13.33
Current Debt
—
—
—
13.33
Other Current Borrowings
—
—
—
13.33
Current Deferred Liabilities
—
—
—
3.25
Current Deferred Revenue
—
—
—
3.25
Total Non Current Liabilities Net Minority Interest
2,299.42
+47.35%
1,560.56
+1.53%
1,536.97
-0.26%
1,540.92
Long Term Debt And Capital Lease Obligation
2,142.63
+42.29%
1,505.80
+0.44%
1,499.25
+0.43%
1,492.77
Long Term Debt
2,142.63
+42.29%
1,505.80
+0.44%
1,499.25
+0.43%
1,492.77
Non Current Deferred Liabilities
42.92
0.00
—
2.25
Non Current Deferred Revenue
—
—
—
2.25
Non Current Deferred Taxes Liabilities
42.92
0.00
—
—
Other Non Current Liabilities
113.86
+107.94%
54.76
+45.17%
37.72
-21.67%
48.16
Stockholders Equity
48.81
-86.58%
363.82
+334.11%
83.81
-50.64%
169.80
Common Stock Equity
48.81
-86.58%
363.82
+334.11%
83.81
-50.64%
169.80
Capital Stock
0.12
-4.07%
0.12
-3.15%
0.13
-5.93%
0.14
Common Stock
0.12
-4.07%
0.12
-3.15%
0.13
-5.93%
0.14
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
117.78
-4.35%
123.14
-2.87%
126.77
-6.20%
135.15
Ordinary Shares Number
117.78
-4.35%
123.14
-2.87%
126.77
-6.20%
135.15
Additional Paid In Capital
12.00
0.00
-100.00%
2.41
-91.20%
27.37
Retained Earnings
54.79
-84.78%
359.87
+297.43%
90.55
-36.77%
143.22
Gains Losses Not Affecting Retained Earnings
-18.09
-572.50%
3.83
+141.27%
-9.28
-906.29%
-0.92
Other Equity Adjustments
-18.09
-572.50%
3.83
+141.27%
-9.28
-906.29%
-0.92
Total Equity Gross Minority Interest
48.81
-86.58%
363.82
+334.11%
83.81
-50.64%
169.80
Total Capitalization
2,191.44
+17.21%
1,869.62
+18.10%
1,583.06
-4.78%
1,662.56
Working Capital
648.12
-31.51%
946.24
+49.27%
633.93
+4.23%
608.22
Invested Capital
2,191.44
+17.21%
1,869.62
+18.10%
1,583.06
-5.54%
1,675.90
Total Debt
2,142.63
+42.29%
1,505.80
+0.44%
1,499.25
-0.45%
1,506.10
Net Debt
2,008.81
+44.52%
1,389.95
+0.66%
1,380.88
+8.57%
1,271.90
Net Tangible Assets
-1,513.01
-232.65%
-454.83
+43.56%
-805.89
-2.54%
-785.90
Tangible Book Value
-1,513.01
-232.65%
-454.83
+43.56%
-805.89
-2.54%
-785.90
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
651.56
+36.01%
479.06
+23.29%
388.57
+61.83%
240.11
Cash Flow From Continuing Operating Activities
651.56
+36.01%
479.06
+23.29%
388.57
+61.83%
240.11
Net Income From Continuing Operations
316.89
-28.64%
444.09
+57.71%
281.59
+39.31%
202.13
Depreciation Amortization Depletion
88.05
+8.29%
81.31
-4.18%
84.86
+70.94%
49.64
Depreciation
11.39
+10.97%
10.26
-7.40%
11.08
+70.69%
6.49
Amortization Cash Flow
76.66
+7.90%
71.05
-3.69%
73.77
+70.98%
43.15
Depreciation And Amortization
88.05
+8.29%
81.31
-4.18%
84.86
+70.94%
49.64
Amortization Of Intangibles
76.66
+7.90%
71.05
-3.69%
73.77
+70.98%
43.15
Other Non Cash Items
298.82
+3450.21%
8.42
+281.95%
-4.63
-166.78%
6.93
Stock Based Compensation
51.56
+18.85%
43.38
+18.47%
36.62
+50.10%
24.40
Asset Impairment Charge
48.70
0.00
0.00
0.00
Deferred Tax
0.63
+19.17%
0.53
-98.46%
34.51
-13.75%
40.01
Deferred Income Tax
0.63
+19.17%
0.53
-98.46%
34.51
-13.75%
40.01
Operating Gains Losses
2.45
+60.97%
1.52
+149.10%
0.61
-67.08%
1.86
Gain Loss On Investment Securities
-0.17
-2342.86%
-0.01
—
1.73
Gain Loss On Sale Of PPE
2.62
+71.42%
1.53
+150.25%
0.61
+373.64%
0.13
Change In Working Capital
-152.26
-70.54%
-89.28
-130.86%
-38.67
+55.01%
-85.95
Change In Receivables
-128.06
-72.49%
-74.25
-2123.57%
-3.34
+96.02%
-83.94
Changes In Account Receivables
-128.06
-72.49%
-74.25
-2123.57%
-3.34
+96.02%
-83.94
Change In Inventory
2.55
+103.79%
-67.38
-150.64%
-26.88
-53.79%
-17.48
Change In Prepaid Assets
-32.96
-715.35%
5.36
+30.70%
4.10
+145.21%
-9.06
Change In Payables And Accrued Expense
6.21
-86.78%
46.99
+474.57%
-12.55
-151.14%
24.54
Investing Cash Flow
-545.81
-107.75%
-262.72
-171.10%
-96.91
+80.10%
-487.00
Cash Flow From Continuing Investing Activities
-545.81
-107.75%
-262.72
-171.10%
-96.91
+80.10%
-487.00
Net PPE Purchase And Sale
-6.97
+34.84%
-10.70
+30.06%
-15.29
-217.96%
-4.81
Purchase Of PPE
-6.97
+34.84%
-10.70
+30.06%
-15.29
-217.96%
-4.81
Sale Of PPE
—
—
—
—
Capital Expenditure
-294.74
-2655.62%
-10.70
+30.06%
-15.29
-217.96%
-4.81
Net Investment Purchase And Sale
474.89
+288.43%
-252.03
-208.80%
-81.61
-116.62%
490.92
Purchase Of Investment
-247.35
+61.80%
-647.60
-121.09%
-292.91
-14.77%
-255.21
Sale Of Investment
722.25
+82.58%
395.57
+87.21%
211.30
-71.68%
746.13
Net Business Purchase And Sale
-725.97
0.00
0.00
+100.00%
-999.12
Purchase Of Business
-725.97
0.00
0.00
+100.00%
-999.12
Net Intangibles Purchase And Sale
-287.77
0.00
0.00
—
Purchase Of Intangibles
-287.77
0.00
0.00
—
Net Other Investing Changes
—
—
—
26.01
Financing Cash Flow
-85.17
+61.08%
-218.86
+46.36%
-407.99
-212.59%
362.37
Cash Flow From Continuing Financing Activities
-85.17
+61.08%
-218.86
+46.36%
-407.99
-212.59%
362.37
Net Issuance Payments Of Debt
451.13
0.00
+100.00%
-13.48
-102.16%
624.55
Issuance Of Debt
1,470.00
0.00
0.00
-100.00%
1,072.00
Repayment Of Debt
-1,018.87
0.00
+100.00%
-13.48
+96.99%
-447.45
Long Term Debt Issuance
1,470.00
0.00
0.00
-100.00%
1,072.00
Long Term Debt Payments
-1,018.87
0.00
+100.00%
-13.48
+96.99%
-447.45
Net Long Term Debt Issuance
451.13
0.00
+100.00%
-13.48
-102.16%
624.55
Net Common Stock Issuance
-342.37
-36.95%
-250.00
+37.87%
-402.38
-101.19%
-200.00
Common Stock Payments
-342.37
-36.95%
-250.00
+37.87%
-402.38
-101.19%
-200.00
Repurchase Of Capital Stock
-342.37
-36.95%
-250.00
+37.87%
-402.38
-101.19%
-200.00
Proceeds From Stock Option Exercised
21.83
-29.90%
31.14
+295.22%
7.88
-43.92%
14.05
Net Other Financing Charges
-215.76
—
—
-76.22
Changes In Cash
20.57
+916.31%
-2.52
+97.83%
-116.33
-200.74%
115.48
Beginning Cash Position
115.85
-2.13%
118.37
-49.56%
234.69
+96.86%
119.22
End Cash Position
136.42
+17.76%
115.85
-2.13%
118.37
-49.56%
234.69
Free Cash Flow
356.82
-23.82%
468.37
+25.47%
373.28
+58.64%
235.30
Interest Paid Supplemental Data
11.43
+8.18%
10.56
-7.41%
11.41
+86.83%
6.11
Income Tax Paid Supplemental Data
134.64
+67.01%
80.62
+153.87%
31.76
+95.73%
16.22
Amortization Of Securities
-3.30
+69.81%
-10.92
-72.78%
-6.32
-671.34%
1.11
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category